Based in Hillsboro of Oregon, FEI designs, manufactures and provides high-performance microscopy workflow solutions, which offer images and information at micro, nano and picometer scales.
Several institutes, universities, pharmaceutical companies, hospitals and others use FEI's solutions in the areas of structural biology, cellular biology, tissue biology, and biomaterials.
With around 3,000 employees, the firm has R&D, sales and manufacturing operations in Europe and the US.
FEI reported revenues of about $930m in the last fiscal year.
The acquired business will be operated under Thermo Fisher’s analytical instruments segment.
Thermo Fisher Scientific president and CEO Marc Casper said: “With FEI’s leading electron microscopy platform, we’re now in an even stronger position to help our life sciences customers accelerate advancements in structural biology.
“FEI is an outstanding strategic fit with our Analytical Instruments business and we will create significant value for our customers by leveraging our global scale and commercial reach to extend the use of these technologies.”
Earlier this year, Thermo Fisher Scientific acquired cellular and genetic analysis products provider Affymetrix for around $1.3bn.
Based in Santa Clara of California, Affymetrix provides products to the customers in various sectors, including life sciences and translational research, molecular diagnostics, reproductive health and agricultural biotechnology.
Image: Thermo Fisher Scientific headquarters in Waltham. Photo: courtesy of Coolcaesar.
